UNSPSC 51172000: Drugs used for gallbladder disease

Drugs that treat disfunction in the human storage reservoir for bile secretion.

UNSPSC 51172000 Drugs used for gallbladder disease is a Class code that in practice encompasses pharmaceutical procurement spanning drug testing supplies, direct-to-manufacturer prescription fulfillment programs, and generic multi-source pharmaceutical distribution through authorized wholesalers to state and local health and criminal justice agencies. State and local issuing bodies under this code include county community supervision and corrections departments, state health and human services agencies, and regional multistate cooperative purchasing alliances representing participating state and local government facilities. The scope of recent solicitations reflects procurement of both pharmaceutical supplies and the services and logistics infrastructure required to deliver them — including specimen collection and drug testing services with lab certification requirements, direct contracting arrangements between state pharmacy benefit programs and manufacturers, and pharmaceutical distribution agreements requiring compliance with cGMP and DSCSA standards, EDI capability, and pricing flexibility across multiple net-price formats.

Recent activity is concentrated in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and an estimated contract value of $600,000 for approximately 25,031 annual tests across two sites in Plano and McKinney. Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription fulfillment without pharmacy benefit managers or group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to maintain relationships with AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. with pricing evaluated at 75 percent weight and contract terms extending through June 30, 2028 for incumbent responders.